A new cancer drug for lung is introduced in European Lung Cancer Conference. It was conducted in Geneva where many other companies presented drugs for various diseases related cancer. AstraZeneca was proved successful over all other drugs for treating or simply delaying the disease for over an year.
Lung Cancer deaths are rising in United States over last years research statistics. US Health Department issued funds last year of more than $118 billion for research into Lung Cancer treatment. AstraZeneca showed various drugs but were a severe failure for company. At the same time, these funding was also at stake and Pfizer applied to take funds for carrying out drug research instead of the above mentioned company.
AstraZeneca has launched its products after United States rejected its patents of Iressa for legality issues. AZD9291 is a recent competitor of this drug. AZD9291 was prepared using Clovis Oncology using genetic mutation technology.
Company is based in London and works mainly on drugs related to Cancer diseases. Its stocks were seen a rise in value for more than 34% over few days after injection of new lung cancer drug in its stock.
Related Stories:
Lung Cancer deaths are rising in United States over last years research statistics. US Health Department issued funds last year of more than $118 billion for research into Lung Cancer treatment. AstraZeneca showed various drugs but were a severe failure for company. At the same time, these funding was also at stake and Pfizer applied to take funds for carrying out drug research instead of the above mentioned company.
AstraZeneca has launched its products after United States rejected its patents of Iressa for legality issues. AZD9291 is a recent competitor of this drug. AZD9291 was prepared using Clovis Oncology using genetic mutation technology.
Company is based in London and works mainly on drugs related to Cancer diseases. Its stocks were seen a rise in value for more than 34% over few days after injection of new lung cancer drug in its stock.
Related Stories:
